vs

Side-by-side financial comparison of ASSEMBLY BIOSCIENCES, INC. (ASMB) and CPS TECHNOLOGIES CORP (CPSH). Click either name above to swap in a different company.

ASSEMBLY BIOSCIENCES, INC. is the larger business by last-quarter revenue ($10.8M vs $8.2M, roughly 1.3× CPS TECHNOLOGIES CORP). CPS TECHNOLOGIES CORP runs the higher net margin — 0.2% vs -85.2%, a 85.4% gap on every dollar of revenue. On growth, ASSEMBLY BIOSCIENCES, INC. posted the faster year-over-year revenue change (57.6% vs 38.3%). CPS TECHNOLOGIES CORP produced more free cash flow last quarter ($-487.0K vs $-15.2M).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

ASMB vs CPSH — Head-to-Head

Bigger by revenue
ASMB
ASMB
1.3× larger
ASMB
$10.8M
$8.2M
CPSH
Growing faster (revenue YoY)
ASMB
ASMB
+19.3% gap
ASMB
57.6%
38.3%
CPSH
Higher net margin
CPSH
CPSH
85.4% more per $
CPSH
0.2%
-85.2%
ASMB
More free cash flow
CPSH
CPSH
$14.7M more FCF
CPSH
$-487.0K
$-15.2M
ASMB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ASMB
ASMB
CPSH
CPSH
Revenue
$10.8M
$8.2M
Net Profit
$-9.2M
$12.6K
Gross Margin
14.9%
Operating Margin
-100.9%
-1.2%
Net Margin
-85.2%
0.2%
Revenue YoY
57.6%
38.3%
Net Profit YoY
4.3%
101.3%
EPS (diluted)
$-0.72
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASMB
ASMB
CPSH
CPSH
Q4 25
$8.2M
Q3 25
$10.8M
$8.8M
Q2 25
$9.6M
$8.1M
Q1 25
$9.4M
$7.5M
Q4 24
$7.4M
$5.9M
Q3 24
$6.8M
$4.2M
Q2 24
$8.5M
$5.0M
Q1 24
$5.8M
$5.9M
Net Profit
ASMB
ASMB
CPSH
CPSH
Q4 25
$12.6K
Q3 25
$-9.2M
$208.0K
Q2 25
$-10.2M
$103.8K
Q1 25
$-8.8M
$96.0K
Q4 24
$-995.2K
Q3 24
$-9.6M
$-1.0M
Q2 24
$-11.2M
$-954.3K
Q1 24
$-9.1M
$-143.2K
Gross Margin
ASMB
ASMB
CPSH
CPSH
Q4 25
14.9%
Q3 25
17.1%
Q2 25
16.5%
Q1 25
16.4%
Q4 24
-4.6%
Q3 24
-12.3%
Q2 24
-4.6%
Q1 24
15.3%
Operating Margin
ASMB
ASMB
CPSH
CPSH
Q4 25
-1.2%
Q3 25
-100.9%
3.1%
Q2 25
-115.2%
1.7%
Q1 25
-105.5%
1.7%
Q4 24
-22.2%
Q3 24
-160.1%
-35.0%
Q2 24
-143.0%
-26.1%
Q1 24
-185.5%
-4.4%
Net Margin
ASMB
ASMB
CPSH
CPSH
Q4 25
0.2%
Q3 25
-85.2%
2.4%
Q2 25
-105.9%
1.3%
Q1 25
-93.6%
1.3%
Q4 24
-16.8%
Q3 24
-140.4%
-24.6%
Q2 24
-130.7%
-19.0%
Q1 24
-156.9%
-2.4%
EPS (diluted)
ASMB
ASMB
CPSH
CPSH
Q4 25
$0.00
Q3 25
$-0.72
$0.01
Q2 25
$-1.33
$0.01
Q1 25
$-1.17
$0.01
Q4 24
$-0.07
Q3 24
$-1.51
$-0.07
Q2 24
$-1.98
$-0.07
Q1 24
$-1.66
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASMB
ASMB
CPSH
CPSH
Cash + ST InvestmentsLiquidity on hand
$22.5M
$13.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$182.7M
$24.6M
Total Assets
$240.0M
$29.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASMB
ASMB
CPSH
CPSH
Q4 25
$13.2M
Q3 25
$22.5M
$4.3M
Q2 25
$24.0M
$3.4M
Q1 25
$23.4M
$3.0M
Q4 24
$38.3M
$4.3M
Q3 24
$28.5M
$5.7M
Q2 24
$19.2M
$7.1M
Q1 24
$18.7M
$8.7M
Total Debt
ASMB
ASMB
CPSH
CPSH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$8.1K
Q3 24
$20.1K
Q2 24
$31.9K
Q1 24
$43.5K
Stockholders' Equity
ASMB
ASMB
CPSH
CPSH
Q4 25
$24.6M
Q3 25
$182.7M
$15.1M
Q2 25
$18.1M
$14.9M
Q1 25
$27.1M
$14.7M
Q4 24
$33.4M
$14.5M
Q3 24
$26.0M
$15.4M
Q2 24
$34.7M
$16.4M
Q1 24
$32.6M
$17.3M
Total Assets
ASMB
ASMB
CPSH
CPSH
Q4 25
$29.5M
Q3 25
$240.0M
$20.4M
Q2 25
$80.8M
$19.4M
Q1 25
$99.0M
$19.2M
Q4 24
$119.2M
$18.9M
Q3 24
$100.3M
$19.2M
Q2 24
$115.3M
$20.1M
Q1 24
$119.9M
$21.2M
Debt / Equity
ASMB
ASMB
CPSH
CPSH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASMB
ASMB
CPSH
CPSH
Operating Cash FlowLast quarter
$-15.1M
$243.6K
Free Cash FlowOCF − Capex
$-15.2M
$-487.0K
FCF MarginFCF / Revenue
-140.7%
-5.9%
Capex IntensityCapex / Revenue
0.4%
8.9%
Cash ConversionOCF / Net Profit
19.34×
TTM Free Cash FlowTrailing 4 quarters
$-479.6K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASMB
ASMB
CPSH
CPSH
Q4 25
$243.6K
Q3 25
$-15.1M
$1.1M
Q2 25
$-16.8M
$649.3K
Q1 25
$-23.4M
$-1.3M
Q4 24
$-51.1M
$-3.5M
Q3 24
$-15.2M
$-1.2M
Q2 24
$-17.1M
$-1.0M
Q1 24
$-18.4M
$128.9K
Free Cash Flow
ASMB
ASMB
CPSH
CPSH
Q4 25
$-487.0K
Q3 25
$-15.2M
$876.8K
Q2 25
$476.4K
Q1 25
$-1.3M
Q4 24
$-51.1M
$-4.5M
Q3 24
$-1.3M
Q2 24
$-17.1M
$-1.6M
Q1 24
$-18.4M
$-134.5K
FCF Margin
ASMB
ASMB
CPSH
CPSH
Q4 25
-5.9%
Q3 25
-140.7%
10.0%
Q2 25
5.9%
Q1 25
-17.9%
Q4 24
-695.2%
-75.3%
Q3 24
-29.8%
Q2 24
-200.6%
-31.8%
Q1 24
-317.7%
-2.3%
Capex Intensity
ASMB
ASMB
CPSH
CPSH
Q4 25
8.9%
Q3 25
0.4%
2.0%
Q2 25
0.0%
2.1%
Q1 25
0.0%
1.2%
Q4 24
0.4%
16.8%
Q3 24
0.0%
1.9%
Q2 24
0.2%
11.0%
Q1 24
0.2%
4.5%
Cash Conversion
ASMB
ASMB
CPSH
CPSH
Q4 25
19.34×
Q3 25
5.05×
Q2 25
6.25×
Q1 25
-13.05×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons